 |
|
| Blog results | Results 1 - 10 of about 23,147 for zetia dose. (0.24 seconds) |
| Sorted by relevance Sort by date |
| 10 Dec 2009 by Dr. Buttar's Blog Mistress “In my practice, I follow previous outcomes studies (and AHA position), ie, niacin is the preferred second agent if statins at maximum tolerated dose do not get patients to target,” Gibbons said. www.abcnews.go.com. Share/Bookmark. Dr. Buttar's Blog - http://www.drbuttar.com/blog/ |
| 17 Nov 2009 by Dr. Walt Zetia reduces ACAT activity and expression because by reducing cholesterol delivery (absorption) ACAT downregulates. There is no cellular cholesterol accumulation on Zetia. In the study quoted, the dose of Zetia that impacted ACAT, ... Dr. Walt's Health Blog - http://www.drwalt.com/blog/ |
| 8 Dec 2009 by Alan Niederman, MD In fact–in every study to date–although the combination of Zetia and statin lowers cholesterol, the endpoints for the study have not been met and Zetia always does worse. My particular problem with the combination is that it is often ... Holy Cross Heart Research Blog - http://holycrossheartresearchblog.com/ |
| 16 Nov 2009 by Kevin “In my practice, I follow previous outcomes studies (and AHA position), i.e., niacin is the preferred second agent if statins at maximum tolerated dose do not get patients to target,” Gibbons said. ... KevinMD.com - http://www.kevinmd.com/blog/ - References [ More results from KevinMD.com ] |
| 16 Nov 2009 But it still shows Niaspan as clearly superior to Zetia, and it makes a person wonder if taking Zetia is basically an expensive way to take a possibly-inadequate dose of simvastatin. In a way, the relatively small size of the study ... In the Pipeline - http://pipeline.corante.com/ - References [ More results from In the Pipeline ] |
| 15 Nov 2009 by Larry Husten ESC: CURRENT-OASIS 7 misses primary endpoint, but high dose clopidogrel aids PCI for ACS .... November 15, 2009 · Leave a Comment The New England Journal of Medicine has published Arbiter 6 — and it could scarcely be any worse, for Zetia. Niaspan's a clear winner; increased risk of cardiac events in patients taking the Zetia arm. Larry Husten has much more — do go read all of his, at CardioBrief. [...] Reply · Kleine Schlappe für Ezetimibe « Medizin&Meinung, ... CardioBrief - http://cardiobrief.org/ - References [ More results from CardioBrief ] |
| 16 Nov 2009 by Deborah Mitchell The researchers found that patients who were taking the extended-release niacin (targeted dose, 2000 mg daily) had less accumulation of plaque and fewer cardiovascular events compared with the patients who were taking Zetia (10 mg ... Emaxhealth - http://www.emaxhealth.com/ [ More results from Emaxhealth ] |
| 15 Nov 2009 by Dr. Matthew Mintz Merk, the makers of Zocor (simvastatin), Zetia, and Vytorin (Zocor + Zetia) funded a trial that, similar to the HALT study, looked at CIMT to measure plaque buildup. It compared simvastatin to the same dose of simvastatin plus Zetia, ... Dr. Mintz' Blog - http://drmintz.blogspot.com/ - References [ More results from Dr. Mintz' Blog ] |
| 17 Nov 2009 by admin Many consumers said that Zetia is not similar to other medicine which is selling in the market. It works through digestive system. So it is less harmful for the heart. According to one High Cholesterol patient, after using half dose for ... letmeget.com - http://www.letmeget.com/ |
| 16 Nov 2009 by nutrocon@aol.com (nutrocon@aol.com) As we reported back in August, a NEJM study confirmed that Niaspan (high-dose prescription B-Vitamin, Niacin) significantly outperformed Zetia and Vytorin in shrinking buildup in artery walls and raisin HDL, the good cholesterol. ... Bonnie's Blog With Bonnie & Steve Minsky - http://nutritionalconcepts.blogspot.com/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
